Maria J De Herdt
Overview
Explore the profile of Maria J De Herdt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stabile R, Cabezas M, Verhagen M, Tucci F, van den Bosch T, De Herdt M, et al.
Cell Death Dis
. 2023 May;
14(5):337.
PMID: 37217493
Cyclin-dependent kinase 2-associated protein 1 (CDK2AP1; also known as deleted in oral cancer or DOC1) is a tumor suppressor gene known to play functional roles in both cell cycle regulation...
2.
Phanthunane C, Wijers R, De Herdt M, Koljenovic S, Sleijfer S, Baatenburg de Jong R, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077836
In early oral squamous cell carcinoma (OSCC), the occurrence of clusters between CD20 B cells and CD4 T cells in the invasive margin (IM) can be captured by using the...
3.
De Herdt M, van der Steen B, Baatenburg de Jong R, Looijenga L, Koljenovic S, Hardillo J
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326642
The receptor tyrosine kinase MET has gained attention as a therapeutic target. Although MET immunoreactivity is associated with progressive disease, use of targeted therapies has not yet led to major...
4.
Mulder E, Verver D, van der Klok T, de Wijs C, van den Bosch T, De Herdt M, et al.
Ann Diagn Pathol
. 2022 Feb;
58:151909.
PMID: 35151198
Objective: Patients with cutaneous melanoma and a positive sentinel node (SN) are currently eligible for adjuvant treatment with targeted therapy and immune checkpoint inhibitors. Near-infrared (NIR) fluorescence imaging could be...
5.
De Herdt M, van der Steen B, van der Toom Q, Aaboubout Y, Willems S, H Wieringa M, et al.
Front Oncol
. 2021 May;
11:638048.
PMID: 33996551
Objective: MET positivity is independently associated with survival in oral squamous cell carcinoma (OSCC). Since MET is a known orchestrator of invasive tumor growth, we investigated its association with LNM...
6.
Aaboubout Y, van der Toom Q, de Ridder M, De Herdt M, van der Steen B, van Lanschot C, et al.
Front Oncol
. 2021 Mar;
11:628320.
PMID: 33777774
Objective: The depth of invasion (DOI) is considered an independent risk factor for occult lymph node metastasis in oral cavity squamous cell carcinoma (OCSCC). It is used to decide whether...
7.
De Herdt M, Koljenovic S, van der Steen B, Willems S, H Wieringa M, Nieboer D, et al.
Hum Pathol
. 2020 Jul;
104:42-53.
PMID: 32702402
Using tissue microarrays, it was shown that membranous C-terminal MET immunoreactivity and ectodomain (ECD) shedding are associated with poor prognosis in oral cancer. Seen the potential diagnostic value, extrapolation of...
8.
De Herdt M, Koljenovic S, van der Steen B, Willems S, Noorlag R, Nieboer D, et al.
Mod Pathol
. 2019 Dec;
33(6):1015-1032.
PMID: 31857683
Ectodomain shedding unleashes the aggressive nature of the MET oncogene product. Using specific C- and N-terminal MET antibodies (D1C2 and A2H2-3), MET protein status (i.e., no MET, decoy MET, transmembranous...
9.
Mohd-Sarip A, Teeuwssen M, Bot A, De Herdt M, Willems S, Baatenburg de Jong R, et al.
Cell Rep
. 2017 Jul;
20(1):61-75.
PMID: 28683324
The Nucleosome Remodeling and Deacetylase (NURD) complex is a key regulator of cell differentiation that has also been implicated in tumorigenesis. Loss of the NURD subunit Deleted in Oral Cancer...
10.
Verhoef E, Kolijn K, De Herdt M, van der Steen B, Hoogland A, Sleddens H, et al.
Oncotarget
. 2016 Apr;
7(21):31029-36.
PMID: 27105539
Tyrosine-kinase inhibitors of the hepatocyte growth factor receptor MET are under investigation for the treatment of hormone-refractory prostate cancer (HRPC) metastasis. Analysis of MET protein expression and genetic alterations might...